A Phase 2 interventional study of Rifaximin in Irritable Bowel Syndrome, sponsored by Bausch Health Americas, Inc.. Completed at 67 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing rifaximin in Irritable Bowel Syndrome — 4 open to participants now, 4 under way, 1 of them phase 3. Rifaximin · Irritable Bowel Syndrome.
Among the 15 studies testing rifaximin in Irritable Bowel Syndrome, this one has the largest planned enrollment, is the only one that started in 2005, is one of 4 in phase 2, and was the 2nd registered.
1,119 studies on the registry are indexed under Irritable Bowel Syndrome; 210 are open to participants now.
Browse Irritable Bowel Syndrome studies →4 of the 15 studies testing rifaximin in Irritable Bowel Syndrome are open now, in 4 countries. Recruiting first, the newest first:
Mark Pimentel, MD · Sites in United States
Ages 18+
University of Malaya · Sites in Malaysia
Ages 18–80
Mahidol University · Sites in Thailand
Ages 18–80
University of Calgary · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →
Of the 129 Irritable Bowel Syndrome studies recruiting now, 34 (26%) set no upper age limit and 85 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 2 · Phase 4 5
First in 2003; this study’s year is marked. 1 started in 2005.
This study's planned enrollment of 525 is above the median of 70 across 898 interventional studies indexed under Irritable Bowel Syndrome.
Median enrollment 92 across the 15 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
10 studies in Irritable Bowel Syndrome by Bausch Health Companies Inc.: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 10 studies in Irritable Bowel Syndrome by Bausch Health Companies Inc., this one is the 4th largest by planned enrollment, is the only one that started in 2005, is one of 7 in phase 2, and was the 2nd registered.
Bausch Health Companies Inc.’s Irritable Bowel Syndrome studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing rifaximin in Irritable Bowel Syndrome, from their registry updates:
Among Bausch Health Companies Inc.’s 10 in Irritable Bowel Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is placebo-controlled study of three rifaximin doses in patients with DIBS. Subjects will be randomized to receive daily doses of placebo BID, rifaximin 275 mg BID, rifaximin 550 mg BID, or 1100 mg BID for 14 days. These four groups will subsequently receive an additional two weeks of placebo for a total of 4 weeks of treatment. A fifth group of subjects will receive rifaximin 550 mg BID for a period of 28 days. Subjects who successfully respond to treatment at the end of the 28-day Treatment Phase will be followed in a Post-treatment Phase that includes study visits during Weeks 6, 8, 12 and 16. Subjects who relapse during the Post-treatment Phase will be discontinued from the study.
While IBS is one of the most common chronic medical conditions the etiology of IBS is unknown. Although not a life-threatening illness, IBS is considered to be a serious condition that has a substantial impact on a subject's day-to-day function. IBS is characterized by abdominal pain and altered bowel habits, including diarrhea, constipation, or alternating diarrhea and constipation. Symptoms are typically intermittent but may be continuous.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The primary objective of this trial is to evaluate the efficacy of a 14-day course of oral rifaximin at 550 mg BID versus placebo in providing adequate relief from Diarrhea-associated IBS (DIBS) symptoms.
To evaluate the dose-response relationship of placebo administered for 28 days and rifaximin administered at 275 mg BID, 550 mg BID, or 1100 mg BID for 14 days;
to evaluate the efficacy of 550 mg BID for 4 weeks to determine if there are any differences when treatment is extended for an additional 2-week period when compared to a similar dosing regimen for 2 weeks;
to evaluate the durability of response over a 12-week Post-treatment Phase in subjects with DIBS who achieved a response during the acute Treatment Phase of the study.
The record gives a start of Dec 2005, a primary completion of Aug 2007 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin
Bausch Health Americas, Inc. →